SUNNYVALE, Calif.--(BUSINESS WIRE)--Silk Road Medical, Inc., a company dedicated to preventing the devastating burden of stroke through surgical innovation, today announced key events at the upcoming Society for Vascular Surgery 2018 Vascular Annual Meeting (VAM) June 20-23 at the Hynes Convention Center in Boston. These include real-world data presentations comparing the company’s TransCarotid Artery Revascularization (TCAR) procedure to transfemoral carotid artery stenting (TFCAS) and carotid endarterectomy (CEA), as well as other company-sponsored events about TCAR.
Two podium presentations will feature data from the Society for Vascular Surgery’s TCAR Surveillance Project, launched in 2016 to obtain real-world comparative outcomes of TCAR and other carotid artery treatments from centers participating in the Vascular Quality Initiative (VQI):
- “In-hospital Outcomes of TransCarotid Artery Revascularization (TCAR) and Carotid Endarterectomy (CEA) in the SVS Vascular Quality Initiative” (VESS05) will be presented by Dr. Marc Schermerhorn of Beth Israel Deaconess Medical Center (Boston) on Wednesday, June 20 at 8:30 a.m. in Room 311.
- “TransCarotid Artery Revascularization (TCAR) vs. Transfemoral Carotid Artery Stenting (TFCAS) in the SVS Vascular Quality Initiative” (SS24) will be presented by Dr. Mahmoud Malas of Johns Hopkins Hospital (Baltimore) on Friday, June 22 at 4:22 p.m. in Ballroom A/B.
Read More: https://www.businesswire.com/news/home/20180618005276/en/Silk-Road-Medical-Announces-Key-Events-Society
Silk Road Medical Announces Key Events for Society for Vascular Surgery 2018 Vascular Annual Meeting
Via: Business Wire
Expanded Phase of Trial will Assess anti-TIGIT in Combination with anti-PD1
All are natural leaders, and they share the same gender and title. But each has taken a different path to Silicon Valley success in the growing healthtech sector, with its own twists and trials.
Via: Omada Health
Digital Therapeutics Pioneer Becomes Largest Diabetes Prevention Program Provider to Achieve Milestone
New Clinical Study: Hinge Health Improves Chronic Knee Pain 61% and Decreases Surgery 63% with Wearable Sensors and Behavioral Coaching
Via: Cision PRWeb
New study shows Hinge Health wearable sensors and coaching significantly improves chronic knee pain without opioids or surgery
Via: Seeking Alpha
Omada Health pulled off something that was, especially at the time, highly unusual in the ever-burgeoning yet still-fledgling digital health space: In 2016, the company scored federal government reimbursements for its diabetes prevention program. It’s continued to grow since then and shared results from nine different peer-reviewed studies noting significant results for diabetes, cardiovascular disease, and obesity patients—a case study in how at least one company in the sphere is using data to try and fuel real world patient outcomes.
OncoMed to Present Multiple Preclinical Abstracts Related to Immuno-Oncology Programs at the 2018 American Association for Cancer Research Annual Meeting
REDWOOD CITY, Calif., April 09, 2018 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED), a clinical-stage biopharmaceutical company focused on discovering and developing novel anti-cancer therapeutics, today announced that five posters will be presented at the upcoming American Association for Cancer Research (AACR) Annual Meeting to be held April 14-18, 2018, in Chicago. Among the presentations will be preclinical data for OncoMed's novel anti-TIGIT (OMP-313M32) immuno-oncology program, which is currently in a Phase 1a single-agent clinical study. Preclinical data for OncoMed's differentiated clinical-stage GITRL-Fc (OMP-336B11) program will also be featured. In addition, preclinical immuno-oncology data for OncoMed's Wnt antagonist vantictumab (anti-FZD, OMP-18R5) in combination with immune checkpoint inhibitors will be presented.
Via: Cision PR Newswire
Plan helps accounts choose the right solutions to keep employees healthy and lower health care costs
Via: FOX17 News
GRAND RAPIDS, Mich. -- There's a new life-saving procedure that's helping patients at Spectrum Health in Grand Rapids.